Comparison of an Artificial Pancreas Versus Threshold Low Glucose Suspend in Type 1 Diabetic Children (SHAN)

Assessment of the Efficacy on the Reduction of Nocturnal Hypoglycemia in Children With Type 1 Diabetes of a Closed-loop Insulin Therapy (Artificial Pancreas) Compared to Insulin Pump Therapy Combined With Continuous Glucose Monitoring With Threshold Low Glucose Suspend of Infusion in Home-like Conditions

The objective of this study is to assess the efficacy of an Artificial Pancreas system which includes a Control-To-Range algorithm, versus standard Insulin Pump Therapy with Threshold Low glucose Suspend feature. 24 Children aged from 7 to 12 will be recruted in 4 clinical centres. After a 2 week run-in period, they will attend two investigational sessions of 65 hours in home-like settings. During each session, the CTR algorithm or the TLGS feature will be activated, depending on the randomization. The main endpoint is the time spent below 70mg/dL between 22:00 and 07:00.

Study Overview

• Status: Completed
• Conditions: Type 1 Diabetes
• Intervention / Treatment: Device: Insulin therapy (aspart, lispro ou glulisine) with Control-to-Range algorithm; Device: Insulin therapy ((aspart, lispro ou glulisine) withThreshold Low Glucose Suspend

Detailed Description

The study is an open randomized control trial preceded by a run-in period and follows a cross-over design.After inclusion, the therapy will be moved to sensor augmented pump therapy with a dedicated training to continuous glucose monitoring using study system (study CGM). During 2 to 3 weeks, the patient will use his/her usual insulin pump and the study CGM (run-in period). At the end of this period, the patient and the relative will be admitted in a parents'house or hotel/resort nearby the hospital for 65 hours to undergo the first interventional session. Admission will be at 17:00 Day 1. The investigator will connect wirelessly the study pump and CGM to the study platform DiAs and remote monitoring will be activated. Until 08:00 Day 2, insulin delivery will be managed in open-loop mode, i.e. insulin doses will be decided according to capillary glucose measurements. From 08:00 Day 2, one algorithm will be activated according to the randomization order, i.e. either the threshold low glucose suspend (TLGS) algorithm (threshold will be set at 70 mg/dl) or the closed-loop algorithm. Insulin delivery will then be managed in open-loop mode with activated TLGS or by the closed-loop algorithm until 08:00 Day 4. In both cases, meals will be of free content and taken around 09:00, 13:00, 17:00 and 20:00. Meal insulin doses will be managed according to pre-meal glucose level and CHO meal content in open-loop mode with TLGS, or according to DiAs bolus calculator suggestion in closed-loop mode. Patient and relative will be encouraged to move in parents'house or hotel/resort and surroundings between meals. The algorithm will be inactivated at 08:00 Day 4. The study pump will be removed and replaced by patient's usual pump. The patient and the relative will be released at 10:00 after breakfast. Study CGM will still be used at home for 2 to 4 weeks until the second interventional session. This session will be similar to the first one but the alternative algorithm will be activated. Patient will come back to pre-study insulin therapy from 08:00 Day 4 and be released at 10:00 when second session is completed.

• Study Type: Interventional
• Enrollment (Actual): 24
• Phase: Phase 2

Contacts and Locations

Study Locations

• France
  • Angers, France, 49000
    • CHU d'Angers
  • Montpellier, France, 34985
    • CHU Montpellier - Hôpital Lapeyronie
  • Paris, France, 75019
    • AP-HP, Hôpital Robert Debré
  • Tours, France, 37000
    • CHU de Tours, Hôpital Clocheville

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 7 years to 12 years (Child)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Age from 7 to 12
2. Puberty status at Prader 1
3. Diabetes diagnosed according to WHO criteria since more than 1 year
4. Fasting plasma C-peptide level <0.2 ng/ml for a fasting blood glucose level < 180 mg/dl
5. At least one positiveness for plasma antibodies against pancreatic islets: IAA, IA2, GAD, ICA or ZnT8, since diagnosis of diabetes
6. Treatment of diabetes by insulin pump since more than 6 months
7. HbA1c level below 8.5%
8. Trained in carbohydrate counting
9. Lack of any associated disease or therapy (except insulin) affecting glucose metabolism
10. Willingness to follow all study procedures
11. Informed consent signed by patient and parent or legally responsible party
12. Patient must be affiliated or beneficiary of a social medical insurance

Exclusion Criteria:

1. Unwillingness of one parent or the legally responsible party to be present during all study procedures
2. Expected use of acetaminophen-containing drugs
3. Any disease or therapy (except insulin) affecting glucose metabolism during previous month
4. Impaired cognitive or psychological abilities which may result in defective adherence to study procedures
5. Active enrollment in another clinical trial or participation in a study within 30 days or participation in previous studies resulting in a cumulated annual income which would exceed 4500 €

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Control-to-Range algorithm and Threshold Low Glucose Suspend; On this arm, patients will realize two investigational sessions: the first with Control-to-Range algorithm (CTR),; the second with Threshold Low Glucose Suspend (TLGS).	Device: Insulin therapy (aspart, lispro ou glulisine) with Control-to-Range algorithm; The insuline used is usual patient insuline. There is no specific insulin for this protocol; Device: Insulin therapy ((aspart, lispro ou glulisine) withThreshold Low Glucose Suspend; The insuline used is usual patient insuline. There is no specific insulin for this protocol
Experimental: Threshold Low Glucose Suspend and Control-to-Range algorithm; On this arm, patients will realize two investigational sessions: the first with Threshold Low Glucose Suspend (TLGS),; the second with Control-to-Range algorithm (CTR).	Device: Insulin therapy (aspart, lispro ou glulisine) with Control-to-Range algorithm; The insuline used is usual patient insuline. There is no specific insulin for this protocol; Device: Insulin therapy ((aspart, lispro ou glulisine) withThreshold Low Glucose Suspend; The insuline used is usual patient insuline. There is no specific insulin for this protocol

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Time spent with blood glucose <70 mg/dl	from 22:00 to 08:00, over two consecutive nights

Secondary Outcome Measures

Outcome Measure	Time Frame
Percent time spent with blood glucose <70mg/dl	over two consecutive days (48h)
Percent time spent with blood glucose level in 70-180 mg/dl range	from 22:00 to 08:00 over two consecutive nights
Percent time spent with blood glucose level in 80-150 mg/dl range	from 22:00 to 08:00 over two consecutive nights
Percent time spent with blood glucose level in 70-180 mg/dl range	over two consecutive days (48h)
Mean blood glucose level	from 22:00 to 08:00, over two consecutive nights
Mean blood glucose level	over two consecutive days (48h)
Number of needed interventions by the patients, the parents, and by the investigational team, to treat hypoglycemia	during 65 hours of each investigational session
Number of needed interventions by the patients, the parents, and by the investigational team, to fix issues related to the functioning of the insulin delivery system	during 65 hours of each investigational session
Score of the Artificial Pancreas Acceptance Questionnaire	at time of inclusion (at Visit 2) and 5 to 6 weeks after inclusion (i.e at Visit 4)
Score of the Hypo Fear Survey	at time of inclusion (at Visit 2) and 5 to 6 weeks after inclusion (i.e at Visit 4)

Collaborators and Investigators

• Sponsor: University Hospital, Montpellier

Publications and helpful links

General Publications

• Renard E, Tubiana-Rufi N, Bonnemaison-Gilbert E, Coutant R, Dalla-Vale F, Farret A, Poidvin A, Bouhours-Nouet N, Abettan C, Storey-London C, Donzeau A, Place J, Breton MD. Closed-loop driven by control-to-range algorithm outperforms threshold-low-glucose-suspend insulin delivery on glucose control albeit not on nocturnal hypoglycaemia in prepubertal patients with type 1 diabetes in a supervised hotel setting. Diabetes Obes Metab. 2019 Jan;21(1):183-187. doi: 10.1111/dom.13482. Epub 2018 Aug 21.

Study record dates

Study Major Dates

• Study Start (Actual): June 16, 2015
• Primary Completion (Actual): December 1, 2016
• Study Completion (Actual): December 1, 2016

Study Registration Dates

• First Submitted: July 8, 2015
• First Submitted That Met QC Criteria: July 23, 2015
• First Posted (Estimate): July 28, 2015

Study Record Updates

• Last Update Posted (Actual): June 14, 2018
• Last Update Submitted That Met QC Criteria: June 12, 2018
• Last Verified: July 1, 2015

More Information

Terms related to this study

• Keywords: Type 1 Diabetes; Artificial Pancreas; T1DM; DiAs platform
• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Immune System Diseases; Autoimmune Diseases; Endocrine System Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 1; Hypoglycemic Agents; Physiological Effects of Drugs; Insulin; Insulin, Globin Zinc; Insulin Aspart; Insulin, Long-Acting; Insulin degludec, insulin aspart drug combination; Insulin Lispro
• Other Study ID Numbers: 9525 (Other Identifier: CTEP)